Form PTO-1449 (modified)	Atty. Docket No. UTSB:721US	Serial No. 10/620,049
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Barrett R. Harvey *et al.*	
	Filing Date: July 15, 2003	Gr up: 1653

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
MJ	A1	5,601,823 A	2/11/1997	Williams *et al.*	424	167.1	12/02/93
V	A2	6,329,156 B1	12/11/01	Cirino *et al.*	435	7.21	03/22/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
MJ	B1	WO 99/36569	01/20/99	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
MJ	C1	Bradley *et al.*, *Nature*, "Identification of the cellular receptor for anthrax toxin," 8;414(6860):225-229, 2001.
	C2	Bull and Parrich, "A binding contract for anthrax," *Science*, 297:201-202, 202.
	C3	Chen and Okayama, "High-efficiency transformation of mammalian cells by plasmid DNA," *Mol. Cell Biol.*, 7(8):2745-2752, 1987.
	C4	Chen *et al.*, "Isolation of high-affinity ligand-binding proteins by periplasmic expression with cyto metric screening," *Nat. Biotechnol.*, 19:537-542, 2001.
	C5	Chen *et al.*, "In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site," *Protein Eng.*, 12:349-356, 1999.
	C6	Daughterty *et al.*, "Quantitative analysis of the effect of the mutation frequency on the affinity maturation of antibodies," *Proc. Natl. Acad. Sci.*, USA, 97:2029-2034, 2000.
	C7	Ezzell *et al.*, "Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin," *Infect. Immun.*, 45:761-777, 1984.
V	C8	Georgiou *et al.*, "Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines," *Nat. Biotechnol.*, 15:29-34, 1997.

25326162.1

EXAMINER: Vanessa Ford | DATE CONSIDERED: 6/17/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSB:721US	Serial No. 10/620,049
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Barrett R. Harvey *et al.*	
	Filing Date: July 15, 2003	Gr up: 1653

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Hayhurst and Georgiou,. "High throughput isolation," *Curr. Opin. Chem. Biol.*, 5:683-689, 2001.
	C10	Hayhurst and Harris, "Escherichia coli Skp chaperone coexpression improves solubility and phage display of single-chain antibody fragments," *Protein Expr. Purif.*, 15:336-343, 1999.
	C11	Hayhurst *et al.*, "Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis," *J. Immunol. Methods*, 276:185-196, 2003.
	C12	Hayhurst, "mproved expression characteristics of single-chain Fv fragments when fused downstream of the Escherichia coli maltose-binding protein or upstream of a single immunoglobulin-constant domain," *Protein Expr. Purif.*, 18:1-10, 2000.
	C13	Hoess, "Protein design and phage display," *Chem. Rev.*, 101:3205-3218, 2001
	C14	Ivins *et al.*, "Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin," *Applies and Environmental Microbiology*, 55:2098-2100, 1989.
	C15	Keller and Stiehm, "Passive immunity in prevention and treatment of infectious diseases," *Clin. Microbiol. Reviews*, 13:602-614, 2000.
	C16	Krebber *et al.*, "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system,"*J. Immunol. Methods*, 201:35-55, 1997.
	C17	Leppla, "Anthrax toxin," Chapter 19 In: *Handbook of Experimental Pharmacology*, 145:445-472, 2000.
	C18	Li *et al.*, "X-ray snapshots of the maturation of an antibody response to a protein antigen," *Nat. Struct. Biol.*, 10(6):482-488, 2003.
	C19	Little *et al.*, "Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus antracis using monoclonal antibodies," *Microbiology*, 142:707-715, 1996.
	C20	Little *et al.*, "Passive protection by polyclonal antibodies against Bacillus antracis infection in guinea pigs," *Infection and Immunity*, 65:5171-5175, 1997.
	C21	Little *et al.*, "Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin," *Infect. Immun.*, 56:1807-1813, 1988.

25326162.1

EXAMINER: Vanessa Ford | DATE CONSIDERED: 6/17/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSB:721US	Serial No. 10/620,049
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Barrett R. Harvey *et al.*	
	Filing Date: July 15, 2003	Group: 1653

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Maynard *et al.*, "Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity," *Nat. Biotechnol.*, 20:597-601, 2002.
	C23	Mourez *et al.*, "Designing a polyvalent inhibitor of anthrax toxin," *Nature Biotechnology*, 19:958-961, 2001.
	C24	Pitt *et al.*, "In vitro correlate of immunity in a rabbit model of inhalational anthrax," Vaccine, 19:4768-4773, 2001.
	C25	Sellman *et al.*, "Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax," *Science*, 292:695-697, 2001.
	C26	Singh *et al.*, "A dominant negative mutant of Bacillus antracis protective antigen inhibits anthrax toxin in vivo," *J. of Biol. Chem.*, 276:22090-22094, 2001.
	C27	Turnbill et al., "Antibodies to Anthrax Toxin in Humans and Guinea Pigs and Their Relevance to Protective Immunity," Abstract, *Med. Microbiol. Immunol.*, 177:293-303, 1988.
	C28	U.S. Patent Application Serial Number 10/288,269, filed November 5, 2002 (UTSB:720US).
	C29	Wittrup, "The single cell as a microplate well," *Nat. Biotechnol.*, 18:1039-1040, 2000.

25326162.1

EXAMINER: [signature] DATE CONSIDERED: 6/17/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.